Nobivac Canine 1-DAPPv a vaccine recommended for use in healthy dogs as an aid in the prevention of disease caused by canine distemper virus, adenovirus type 1 (hepatitis) and adenovirus type 2 (respiratory disease), canine parainfluenza virus, and canine parvovirus. Protects against all known strains of CPV, including CPV-2c.1-2 High antigenic mass (titer), low passage parvovirus vaccine Canine vaccine containing CPV-2b, one of the most prevalent field strains of parvovirus Protects against 2 types of adenovirus that cause hepatitis and respiratory disease in dogs Provides disease coverage for commonly spread canine viruses, distemper, adenovirus types 1 and 2, parainfluenza and parvovirus in 1 formula First to publish data showing protection against CPV-2c challenge.1 Multiple studies demonstrate the ability to override maternal antibodies.3
Canine Distemper, Adenovirus Type 2, Parainfluenza, Parvovirus Vaccine, MODIFIED LIVE VIRUS Proven 1-year vacine that offers broad protection against ccanine parvovirus (CPV), adenovirus type 1 (hepatitis) and type 2 (respiratory disease), parainfluenza, and distemper.
Indications Approved for the vaccination of healthy dogs as an aid in the precention of disease caused by canine distemper virus, adenovirus types 1 and 2, parainfluenza, and parvovirus Recommended for use in healthy dogs 6 weeks of age or older
Nobivac is a registered trademark of Intervet Inc., d/b/a Merck Animal Health, a subsidiary of Merck & Co. Inc.
Transfer contents of the sterile diluent vial to the Nobvac Canine 1-DAPPv vial aseptically. Mix gently until dissolved. Use entire contents immediately after rehydration.
Subcutaneous or intramuscular injection
Primary vaccination may begin as early as 6 weeks. repeat at 2 to 4 week intervals until the dog is 12 weeks of age.
Annual revaccination with 1 dose is recommended: Following the advice of The American Veterinary Medical Association on Vaccination Principles, an appropriate revaccination program for individual animals should be made based upon veterinarian-client patient relationships
Inject one dose (1ml) Subcutaneously or intramuscularly. The initial dose ma be given at 6 weeks of age or older. Repeat at 2 to 4 week intervals until the dog is 12 weeks of age. A minimum of two doses is required for primary immunization. Annual revaccination with one dose is recommended. Following the advice of the American Veterinary Medical Association on Vaccination Principles, an appropriate revaccination program for individual animals should be made based upon veterinarian-client-patient relationships.
SAFETY INFORMATION: Please see the product label for safety information.
Store at 2°-7°
Do not freeze.
Do not mix with other vaccines.
Use new, non-chemically sterilized needles and syringes.
Burn vaccine container and all unused contents.
Contains gentamicin as a preservative.
Vaccinate only health, non-parasitized dogs.
Do not vaccinate pregnant bitches.
The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.
The age at which maternal antibody for canine parvovirus no longer interferes with the development of active immunity varies according to the bitch's titer and quantity of colostral antibodies absorbed by the puppy.